The ICPO Theranostics Summit 2024 marked an exciting milestone for the global Theranostics community, bringing together international experts to explore a new era of alpha emitters and radiopharmaceuticals in precision oncology. Hosted virtually by the ICPO Foundation, the two-day event provided a dynamic platform for knowledge exchange, innovation, and collaboration among leading specialists from academia, industry, and clinical practice.
The chairs, Prof. Richard P. Baum and Prof. Frederik L. Giesel, guided participants through the latest scientific and clinical developments, shaping the future of Radiotheranostics. The first day focused on the rapidly advancing field of alpha emitters, with in-depth insights into key isotopes including Actinium (Ac), Astatine (At), and Lead (Pb) and their potential to transform targeted cancer therapy. On the second day, attention turned to innovative radiopharmaceutical targets, highlighting the emerging clinical impact of FAP, CA9, CXCR4, and GPC3 in diagnosis and treatment.
ICPO Summit Invitation
ICPO Summit Recap
